All In Biotech

Drug Trial Radar · NCT05125809

Setrusumab vs Placebo for Osteogenesis Imperfecta

An Operationally Seamless, Randomized Phase 2/3 Study Consisting of a Phase 2 Single-Blind, Dose-Evaluation Phase and a Phase 3 Double-Blind, Placebo-Controlled Phase to Assess the Efficacy and Safety of Setrusumab in Subjects With Osteogenesis Imperfecta

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 183 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

183

Actual

Start

Feb 21, 2022

Primary completion

Oct 20, 2025

Study completion Apr 2027

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
Collaborators
Mereo BioPharma
First posted
Nov 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs placebo on reduction in fracture rate.

Conditions

  • Osteogenesis Imperfecta

Interventions

  • SetrusumabBiological

    A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion

  • PlaceboOther

    A 5% dextrose/glucose solution administered QM via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Percent Change in Serum Amino-terminal Propeptide of Type 1 Procollagen (P1NP) from Baseline at Month 1Time frame: Baseline, Month 1
  2. Phase 3: Annualized Rate of All Radiographically-Confirmed Fractures, Excluding Morphometric Vertebral Fractures and Fractures of the Fingers, Toes, Face, and Skull at the Primary AnalysisTime frame: Up to Month 24

Locations

43 sites in 11 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Shriners Hospital for Children - Northern California

    Sacramento, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Yale New Haven Hospital

    New Haven, Connecticut

  • Nemours/ Alfred i. duPoint Hospital for Children

    Wilmington, Delaware

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • University of South Florida

    Tampa, Florida

  • Shriners Hospitals for Children - Chicago

    Chicago, Illinois

  • Indiana University Hospital

    Indianapolis, Indiana

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • Children's Hospital and Medical Center

    Omaha, Nebraska

  • New Mexico Clinical Research & Osteoporosis Center, Inc.

    Albuquerque, New Mexico

  • Atrium Health Levine Children's Hospital

    Charlotte, North Carolina

  • Nationwide Children's Hospital- Ohio State University College of Medicine

    Columbus, Ohio

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Cook Children's Medical Center

    Fort Worth, Texas

  • Baylor College of Medicine

    Houston, Texas

  • UW Health University Hospital

    Madison, Wisconsin

  • Royal Children's Hospital

    Melbourne, Australia

  • Queensland Paediatric Endocrinology

    South Brisbane, Queensland, Australia

  • McGill University Health Centre

    Montreal, Canada

  • University of Toronto- The Hospital for Sick Children (SickKids)

    Toronto, Canada

  • London Health Sciences Center

    London, Ontario, Canada

  • Children's Hospital of Eastern Ontario

    Ottawa, Ontario, Canada

  • Institut Imagine

    Paris, France

  • University of Cologne

    Cologne, Germany

  • Otto von Guericke University Magdeburg

    Magdeburg, Germany

  • Musculoskeletal Center Würzburg

    Würzburg, Germany

  • Istituto Ortopedico Rizzoli

    Bologna, Italy

  • Azienda Ospedaliera Universitaria Policlinico Umberto I

    Rome, Italy

  • Universita Degli Studi Di Verona

    Verona, Italy

  • Wilhelmina Children's Hospital

    Utrecht, Netherlands

  • Uniwersytet Medyczny w Lodzi - Klinika Endokrynologii i Chorob Metabolicznych

    Lodz, Poland

  • Hospital de Santa Maria

    Lisbon, Portugal

  • Centro Hospitalar do Porto

    Porto, Portugal

  • Gazi University

    Ankara, Turkey (Türkiye)

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.